Evidence map›Paper›PMID 35869555›Full record

ArticleJournal of experimental & clinical cancer research : CR2022

ARHGEF37 overexpression promotes extravasation and metastasis of hepatocellular carcinoma via directly activating Cdc42.

Xin Zhang, Liangliang Ren, Junhua Wu, Rongni Feng, Yunyang Chen, Ronggang Li, Meimei Wu, Mingzhu Zheng, Xing Gui Wu, Wanjun Luo and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. [RGL1 overexpression promotes metastasis of colorectal cancer by upregulating motile focal adhesion assemblyNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Xin Zhang *Clinical Experimental Center, Jiangmen Key Laboratory of Clinical Biobanks and Translational Research, Jiangmen Central Hospital, Jiangmen, 529030, China.
Liangliang Ren *Clinical Experimental Center, Jiangmen Key Laboratory of Clinical Biobanks and Translational Research, Jiangmen Central Hospital, Jiangmen, 529030, China.
Junhua Wu *Department of Hepatobiliary, Pancreatic and Splenic Surgery, Jiangmen Central Hospital, Jiangmen, 529030, China.
Rongni FengDepartment of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Yunyang ChenDepartment of Hepatobiliary, Pancreatic and Splenic Surgery, Jiangmen Central Hospital, Jiangmen, 529030, China.
Ronggang LiDepartment of Pathology, Jiangmen Central Hospital, Jiangmen, 529030, China.
Meimei WuClinical Experimental Center, Jiangmen Key Laboratory of Clinical Biobanks and Translational Research, Jiangmen Central Hospital, Jiangmen, 529030, China.
Mingzhu ZhengClinical Experimental Center, Jiangmen Key Laboratory of Clinical Biobanks and Translational Research, Jiangmen Central Hospital, Jiangmen, 529030, China.
Xing Gui WuDepartment of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Wanjun LuoDepartment of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Hongle HeDepartment of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Yanming HuangClinical Experimental Center, Jiangmen Key Laboratory of Clinical Biobanks and Translational Research, Jiangmen Central Hospital, Jiangmen, 529030, China.
Miaoling TangCancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, Guangdong, China. tangmling3@mail2.sysu.edu.cn.ORCID http://orcid.org/0000-0003-3488-2139
Jun LiClinical Experimental Center, Jiangmen Key Laboratory of Clinical Biobanks and Translational Research, Jiangmen Central Hospital, Jiangmen, 529030, China. lijun37@mail.sysu.edu.cn.
Jiangmen Central Hospital · CNSun Yat-sen University · CN

Funding

Medical Science and Technology Foundation of Guangdong Province 2018A030310007Medical Science and Technology Foundation of Guangdong Province 2019030102430012905Medical Science and Technology Foundation of Guangdong Province 2019A1515011565Medical Science and Technology Foundation of Guangdong Province 2020030103140008978Medical Science and Technology Foundation of Guangdong Province 2021A1515012432National Natural Science Foundation of China 81802918National Natural Science Foundation of China 81830082National Natural Science Foundation of China 82030078National Natural Science Foundation of China 82103582Postdoctoral Research Foundation of China 2019M660206
6 · The paper itself

Abstract

backgroundThe extravasation capability of hepatocellular carcinoma (HCC) cells plays a vital role in distant metastasis. However, the underlying mechanism of extravasation in HCC lung metastasis remains largely unclear.

methodsThe expression of ARHGEF37 in human HCC specimens and HCC cell lines was examined by quantitative RT-PCR, western blot, and immunohistochemistry (IHC) analyses. The biological roles and mechanisms of ARHGEF37/Cdc42 in promoting lung metastasis were investigated in vitro and in vivo using cell lines, patient samples, xenograft models.

resultsIn the current study, we found that Rho guanine nucleotide exchange factor 37 (ARHGEF37) was upregulated in human HCC samples and was associated with tumor invasiveness, pulmonary metastasis and poor prognosis. Overexpressing ARHGEF37 significantly enhanced the extravasation and metastatic capability of HCC cells via facilitating tumor cell adhesion to endothelial cells and trans-endothelial migration. Mechanistically, ARHGEF37 directly interacted with and activated Cdc42 to promote the invadopodia formation in HCC cells, which consequently disrupted the interaction between endothelial cells and pericytes. Importantly, treatment with ZCL278, a specific inhibitor of Cdc42, dramatically inhibited the attachment of ARHGEF37-overexpressing HCC cells to endothelial cells, and the adherence and extravasation in the lung alveoli, resulting in suppression of lung metastasis in mice.

conclusionOur findings provide a new insight into the underlying mechanisms on the ARHGEF37 overexpression-mediated extravasation and pulmonary metastasis of HCC cells, and provided a potential therapeutic target for the prevention and treatment of HCC pulmonary metastasis.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsLung NeoplasmsAnimalsCell Line, TumorCell MovementEndothelial CellsGene Expression Regulation, NeoplasticHumansMiceNeoplasm MetastasisExtravasationHCCMetastasisRho guanine nucleotide exchange factor

Identifiers

PMID35869555
PMCPMC9308268
OpenAlexW4286586897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.